Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Long-term Safety in Rheumatoid Arthritis (China Extension)
CTR20130934Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2015
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Jun 2015; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20130934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130934.